Endo, Inc.
Endo, Inc. operates as a specialty pharmaceutical company that develops, manufactures, markets, and sells various pharmaceutical products and provides life-enhancing therapies in the United States and internationally. It offers specialty medicines, sterile injectables, and generic products. The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology. It … Read more
Endo, Inc. (NDOI) - Net Assets
Latest net assets as of March 2025: $1.13 Billion USD
Based on the latest financial reports, Endo, Inc. (NDOI) has net assets worth $1.13 Billion USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.19 Billion) and total liabilities ($3.06 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.13 Billion |
| % of Total Assets | 26.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Endo, Inc. - Net Assets Trend (2023–2024)
This chart illustrates how Endo, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Endo, Inc. (2023–2024)
The table below shows the annual net assets of Endo, Inc. from 2023 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.25 Billion | +118.98% |
| 2023-12-31 | $-6.60 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Endo, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1462356300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $1.98 Billion | 158.36% |
| Total Equity | $1.25 Billion | 100.00% |
Endo, Inc. Competitors by Market Cap
The table below lists competitors of Endo, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sabine Royalty Trust
NYSE:SBR
|
$1.02 Billion |
|
Lier Chemical Co Ltd
SHE:002258
|
$1.02 Billion |
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
$1.02 Billion |
|
BaoJi Titanium Industry Co Ltd
SHG:600456
|
$1.02 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
$1.02 Billion |
|
Micro Tech Nanjing Co Ltd
SHG:688029
|
$1.02 Billion |
|
Lincoln Educational Services
NASDAQ:LINC
|
$1.02 Billion |
|
Pilot Corporation
OTCGREY:POGHF
|
$1.02 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Endo, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -6,597,560,000 to 1,252,338,000, a change of 7,849,898,000.
- Other factors increased equity by 7,849,898,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $0.00 | -0.0% |
| Other Changes | $7.85 Billion | +626.82% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Endo, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.54x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $-104.57 | $25.30 | x |
| 2024-12-31 | $16.43 | $25.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Endo, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -121.79%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 0.00x
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 0.00% | -121.79% | 0.39x | 0.00x | $-1.79 Billion |
Industry Comparison
This section compares Endo, Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Endo, Inc. (NDOI) | $1.13 Billion | 0.00% | 2.72x | $1.02 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |